Dexamethasone Bene Pharm IV IM Solution for Injection 4mg/1ml Ampoule #40

Name - Dexamethasone Bene Pharm IV IM Solution for Injection 4mg/1ml Ampoule /Rum/ #40 Indications for use - Endocrine disorders: Acute adrenal insufficiency; surgical interventions, severe trauma or diseases in patients with known or suspected adrenal insufficiency. - Various genesis shock: Shock resistant to standard therapy; anaphylactic shock; shock in patients with adrenal insufficiency. - Cerebral edema: Cerebral edema caused by primary or metastatic brain tumors, neurosurgical intervention or craniocerebral trauma. - Malignant diseases: Palliative treatment of leukemia and lymphoma in adults, acute leukemia in children; hypercalcemia in patients with malignant tumors when oral treatment is not possible. - Exacerbation of chronic obstructive bronchitis and bronchial asthma, asthmatic status. - Severe allergic reactions. - Intra-articular administration: In cases of pronounced joint inflammation (excluding infectious), when conventional therapy is ineffective, as well as in other conditions with synovitis (after aspiration of synovial fluid). - Local use (in the affected area) is indicated in cases of nodular prurigo, granuloma annulare, and sarcoidosis. - Subconjunctival, retrobulbar or peribulbar administration: Indicated in cases where there is a risk to vision in inflammatory or allergic diseases of the eyes, systemic immunodeficiency, proliferative changes of the orbit, sympathetic ophthalmia, and after immunosuppressive treatment following corneal transplantation. Diagnostic examination of adrenal gland hyperfunction. In this dosage form, the drug Dexamethasone is also indicated for the treatment of a number of diseases when oral forms of Dexamethasone cannot be used. Method of administration and dosage Parenteral administration The preparation is administered intramuscularly, intravenously by bolus or infusion (with glucose or saline). Dexamethasone should not be mixed with other medicinal products in the same syringe or infusion bottle. Recommended initial average daily doses for intravenous or intramuscular administration range from 0.5 to 9 mg per day, or more if necessary. 4-20 mg of Dexamethasone can be administered 3-4 times a day. The duration of parenteral administration is usually 3-4 days, after which maintenance therapy with the oral form of the preparation is initiated. Local administration (in the affected area) Recommended doses are 0.4-4 mg intra-articularly once. Intra-articular injections can be repeated after 3-4 months. The preparation can be administered a maximum of 3-4 times in the same joint per year. Administration to two joints simultaneously is possible. More frequent use may lead to damage of the joint cartilage. The dose of the preparation depends on the size of the affected joint. In large joints, 2-4 mg of Dexamethasone is usually administered, and 0.8-1 mg in small joints. Doses for administration into the synovial bursa are 2-3 mg, the dose for administration into the tendon sheath is 0.4-1 mg, and the dose for administration into the tendon is 1-2 mg. The dose of Dexamethasone administered into the affected area is equal to the dose administered into the joint. The preparation can be administered to a maximum of 2 affected areas simultaneously. For administration into soft tissues, a dose of 2-6 mg is recommended (around the joint). Doses for children (intramuscularly) During replacement therapy (in case of adrenal insufficiency), the dose of the preparation is 0.0233 mg per kg of body weight or 0.67 mg per m2 of body surface area, divided into 3 doses, every third day, or 0.00776-0.01165 mg per kg of body weight or 0.233-0.335 mg per m2 of body surface area daily. For other indications, the recommended dose is 0.02776-0.16665 mg per kg of body weight or 0.833-5 mg per m2 of body surface area every 12-24 hours